Oral Contraceptives—A Continuing Reappraisal

Abstract

Recent studies have associated the rare thromboembolic complications with the estrogen content of the Pill and the age of the user. Contraceptive polyp and postcontraceptive amenorrhea must be differentiated from tumors. Adverse metabolic effects may occur in individuals with an underlying defect of hepatic, triglyceride or porphyrin metabolism. Use of the Pill is neither associated with an increased incidence of monilial vaginitis nor followed by a period of “rebound hyperfertility.”